Allergan (AGN) Tops Q2 EPS by 8c; Boosts Forecast

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/13/2026

1. WDAY
2. JNJ
3. AAPL
4. META
5. NRIX
6. SUNS
7. CRDO
8. OIG
9. AMAT
10. SPY

Go back to Allergan (AGN) Tops Q2 EPS by 8c; Boosts Forecast

Allergan (AGN) & Medicines360 Granted NDA Approval for LILETTA (levonorgestrel-releasing intrauterine system) 52 mg

August 7, 2017 8:07 AM EDT

Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women's health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for the prevention of pregnancy for up to four years.

"The newly approved indication for LILETTA is an important milestone in... More